Literature DB >> 6831827

Verapamil plasma binding: relationship to alpha 1-acid glycoprotein and drug efficacy.

F X McGowan, M J Reiter, E L Pritchett, D G Shand.   

Abstract

The relationship between alpha 1-acid glycoprotein (AAG) plasma concentration and plasma verapamil binding was examined in samples obtained 15 minutes after 10 mg IV verapamil to 15 subjects. There was a good correlation (r = 0.83) between the binding ratio and AAG concentration, suggesting that AAG could bind verapamil. This was confirmed in vitro by the addition of AAG to an albumin solution, which resulted in a strong correlation between binding ratio (r = 0.99) and AAG concentration. The relationship between both free and total plasma concentrations and the effects of verapamil on the PR interval was also examined several times after 10 mg IV verapamil in seven of the subjects. While there was a correlation between log of both concentrations and the percent prolongation in PR interval (P less than 0.001), the correlation was stronger with free drug concentration (r2 = 0.58) than with total plasma concentration (r2 = 0.36). The range of free concentrations associated with a given effect (220%) was also narrower than that for total concentration (300%). While these data indicate that AAG is responsible for most of the variability in plasma verapamil binding, which in turn contributes somewhat to variation in effectiveness of a given total plasma concentration, neither of these causes of individual variations is likely to have a major clinical impact in patients who, apart from arrhythmia, are otherwise healthy.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6831827     DOI: 10.1038/clpt.1983.66

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  17 in total

1.  Influence of menstrual cycle phase on serum concentrations of alpha 1-acid glycoprotein.

Authors:  R C Parish; C Spivey
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

Review 2.  Do calcium antagonists have a place in the treatment of mood disorders?

Authors:  C Höschl
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

3.  Serum binding of nifedipine and verapamil in patients with ischaemic heart disease on monotherapy.

Authors:  D O Rumiantsev; V K Piotrovskii; V I Metelitsa; I D Slastnikova; E V Kokurina
Journal:  Br J Clin Pharmacol       Date:  1989-09       Impact factor: 4.335

4.  Characterization of solution-phase drug-protein interactions by ultrafast affinity extraction.

Authors:  Sandya R Beeram; Xiwei Zheng; Kyungah Suh; David S Hage
Journal:  Methods       Date:  2018-03-03       Impact factor: 3.608

5.  Chromatographic studies of drug interactions with alpha1-acid glycoprotein by ultrafast affinity extraction and peak profiling.

Authors:  Sandya Beeram; Cong Bi; Xiwei Zheng; David S Hage
Journal:  J Chromatogr A       Date:  2017-03-23       Impact factor: 4.759

Review 6.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

7.  alpha 1-Acid glycoprotein and plasma lidocaine binding.

Authors:  D G Shand
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

Review 8.  Poisoning due to calcium antagonists. Experience with verapamil, diltiazem and nifedipine.

Authors:  P D Pearigen; N L Benowitz
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

Review 9.  Interpretation of drug levels in acute and chronic disease states.

Authors:  E Perucca; R Grimaldi; A Crema
Journal:  Clin Pharmacokinet       Date:  1985 Nov-Dec       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.

Authors:  H Echizen; M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.